Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02793544 · ClinicalTrials.gov registry record · Phase 2
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
A Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Myelodysplastic Syndrome (MDS), sponsored by Center for International Blood and Marrow Transplant Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 11
- Study locations
NCT02793544 is a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Myelodysplastic Syndrome (MDS) that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 80 participants, below the 189-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (58% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT02793544, a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Myelodysplastic Syndrome (MDS), has completed, sponsored by Center for International Blood and Marrow Transplant Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil (MMF) for graft versus host disease (GVHD) prophylaxis in patients with hematologic malignancies.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
- RADIATION Total Body Irradiation (TBI) 200cGy on Day -1
- PROCEDURE Infusion of non-T-cell depleted bone marrow on Day 0
Study Locations (11)
Florida
- Shands HealthCare & University of Florida - Gainesville
- University of Miami - Miami
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Maryland
- University of Maryland Greenebaum Cancer Center - Baltimore
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - Adults - New York
North Carolina
- University of North Carolina Hospitals - Chapel Hill
Ohio
- Ohio State Medical Center, James Cancer Center - Columbus
Virginia
- Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program - Richmond
Wisconsin
- Froedtert Memorial Lutheran Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-12 |
| Est. Completion | 2020-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02793544
The ClinicalTrials.gov registry entry for NCT02793544 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (58% lower). The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT02793544 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Florida, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT02793544 about?
NCT02793544 is a clinical study titled "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide". This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil (MMF) for graft versus host ...
What is the current status of trial NCT02793544?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-12. Estimated completion is 2020-03.
What conditions does trial NCT02793544 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma.
What interventions are being tested in trial NCT02793544?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5 (DRUG), Total Body Irradiation (TBI) 200cGy on Day -1 (RADIATION), Infusion of non-T-cell depleted bone marrow on Day 0 (PROCEDURE).
Who is sponsoring clinical trial NCT02793544?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02793544 being conducted?
This trial has 11 study locations across Florida, Maryland, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
RECRUITING · Phase 2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
ACTIVE NOT RECRUITING · Phase 2
-
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Chronic Lymphocytic Leukemia (CLL)
All registered trials for this condition
Myelodysplastic Syndrome (MDS)
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.